Listen
HUMIRA (adalimumab), anti-TNFα
DERMATOLOGY - New indication
Opinions on drugs -
Posted on
May 26 2016
Reason for request
Extension of indication
Insufficient actual benefit in the management of moderate to severe hidradenitis suppurativa (Verneuil's disease).
- HUMIRA now has Marketing Authorisation in the treatment of active, moderate to severe hidradenitis suppurativa (Verneuil's disease) in adults in case of insufficient response to conventional systemic treatment.
- Its efficacy, assessed by a clinical score of little relevance, is modest and limited in time. There are no data on access to or facilitation of the surgical procedure.
- No benefit on quality of life, which is particularly impaired in this disease, has been demonstrated.
- Long-term safety data in this indication are limited.
Clinical Benefit
| Insufficient |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
